Genetech’s Roche unit agreed to pay $20 Million to resolve allegations related to the company’s off-label marketing of Rituxan, a drug then-approved to treat non-Hodgkin’s lymphoma.  According to the complaint, Genetech trained physicians to use Rituxan for unapproved uses and encouraged sales representatives to push off-label prescriptions.

Read the entire article, “Genetech to Pay $20 Million in Rituxan Whistleblower Suit”